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TGF- inhibits proliferation of prostate epithelial cells. How-
ever, prostate cancer cells in advanced stages become resistant
to inhibitory effects of TGF-. The intracellular signaling mech-
anisms involved in differential effects of TGF- during different
stages are largely unknown. Using cell line models, we have
shown that TGF- inhibits proliferation in normal (RWPE-1)
and prostate cancer (DU145) cells but does not have any effect
on proliferation of prostate cancer (PC3) cells. We have investi-
gated the role of Jun family proteins (c-Jun, JunB, and JunD) in
TGF- effects on cell proliferation. Jun family members were
expressed at different levels and responded differentially to
TGF- treatment. TGF- effects on JunD protein levels, but not
mRNA levels, correlated with its effects on cell proliferation.
TGF- induced significant reduction in JunD protein in
RWPE-1 and DU145 cells but not in PC3 cells. Selective knock-
down of JunD expression using siRNA in DU145 and PC3 cells
resulted in significant reduction in cell proliferation, and forced
overexpression of JunD increased the proliferation rate. On the
other hand, knockdown of c-Jun or JunB had little, if any, effect
on cell proliferation; overexpression of c-Jun and JunB
decreased the proliferation rate in DU145 cells. Further studies
showed that down-regulation of JunD in response to TGF-
treatment is mediated via the proteasomal degradation path-
way. In conclusion, we show that specific Jun family members
exert differential effects on proliferation in prostate cancer cells
in response to TGF-, and inhibition of cell proliferation by
TGF- requires degradation of JunD protein.
TGF- is a secreted cytokine that acts as a major anti-prolif-
erative factor in the initial stages of prostate cancer, whereas in
the advanced stages of prostate cancer, it acquires pro-onco-
genic and pro-metastatic properties (1–3). The TGF- cyto-
kine exists in three major isoforms: TGF-1, TGF-2, and
TGF-3. TGF- ligands bind to a heterodimeric receptor com-
plex consisting of two serine-threonine kinase receptors, desig-
nated TGF- type I and type II receptors, and leads to activation
of several intracellular pathways (4 –7). Concomitant with the
switch of TGF- from growth-inhibitory to growth-promoting
signal, expression of TGF- ligands and receptors is known to
be altered in prostate cancer relative to normal prostate cells
and is further altered in more aggressive androgen-refractory
prostate cancer cells (8, 9). Expression of TGF- and its family
members is also associated with poor prognosis (10 –12). It has
also been shown that loss of TGF- type II receptor expression
correlates with increasing tumor aggressiveness in prostate
cancer (8). However, a significant fraction of prostate cancers
become TGF--resistant without mutation, deletion, or down-
regulation of TGF- receptors or Smads or other downstream
signaling molecules.
Previous studies have shown different effects of TGF-1 on
proliferation of different prostate cancer cell lines; TGF-
inhibits proliferation of DU145 cells but has no effect on pro-
liferation of PC3 cells in the presence of functional TGF-
receptors and Smad signaling (13–16), indicating differences in
signaling mechanisms in two cell lines downstream of receptor-
dependent Smad activation that are responsible for differential
effects of TGF- on cell proliferation. TGF- is a pleiotropic
cytokine whose signaling outcome is known to depend on the
combination of available contributing factors and active path-
ways in each target tissue. Previous reports have shown that
other intracellular proteins influence TGF- effects (17–19). It
has been well established that extensive interactions exist
between the TGF- signaling pathway and other major signal-
ing pathways, including Wnt, Notch, Hedgehog, JNK, MAPK,
and AKT/PI3K (20 –24). It is also becoming apparent that
TGF- signaling intersects with several transcription factors
and regulators, such as GL1, SOX4, Tieg3/Klf11, Id, and AP-1
proteins (25–29). Many studies have implicated AP-1 proteins
in TGF- signaling (30 –32). The AP-1 family consists of
dimeric protein complexes composed of different Jun proteins
(c-Jun, JunB, and JunD) and four Fos proteins (c-Fos, FosB,
Fra1, and Fra2). These proteins form Jun-Jun homodimers and
Jun-Fos heterodimers and bind to the 12-O-tetradecanoylphor-
bol-13-acetate response element, TGACTCA palindromic
sequence, in the promoters of target genes (33, 34). AP-1 pro-
teins have been shown to be involved in cell proliferation,
inflammation, differentiation, apoptosis, wound healing, and
carcinogenesis (35–38). Among the AP-1 proteins, there is
growing evidence that Jun proteins play a major role in the
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control of cell proliferation and cell death by regulating the
expression of cell cycle regulators (39 – 42). In prostate cancer,
expression of AP-1 proteins has recently been associated with
disease recurrence and more aggressive clinical outcome (43,
44).
Within the last few years, several studies have suggested the
involvement of Jun proteins in prostate cancer growth, survival,
and metastasis. For example, c-Jun has been shown to enhance
androgen-dependent cell proliferation and inhibition of apo-
ptosis in LNCaP cells (43, 45), but it mediates the action of a
metastasis suppressor gene, KAI1, in PC3 and DU145 cells (46).
JunD, along with Fra1 and Fra2, has also been reported to be
essential in prostate cancer proliferation and confers protec-
tion against radiation-induced cell death (47). In a recent
report, JunB was shown to play an important role in maintain-
ing cell senescence that blocks malignant prostate cell transfor-
mations (48) and has been shown to be a potent activator of
KAI1 (49). Jun proteins by themselves or in combination with
members of the Fos proteins have also been implicated in the
actions of androgens (50, 51), atmospheric pollutants (52),
growth factors (53), phytochemicals (54 –56), peroxides (57),
isothiocyanates (58), glycoproteins (59), and, most recently,
proteasome inhibitors (60). AP-1 proteins form multiple
homo- and heterodimers, and the composition of these dimers
may dictate expression of specific genes involved in specific
biological responses. However, the specific roles of individual
AP-1 family members in the development and progression of
prostate cancer are still largely unknown. Few reports have
shown the effects, if any, of TGF- on AP-1 in prostate cancer
(61– 63).
The present study was carried out to determine specific roles
of Jun family members in TGF- effects on proliferation in
prostate cancer cells. Our results indicate that JunD is essential
for proliferation of prostate epithelial cells, and the inhibitory
effects of TGF- on cell proliferation are dependent on degra-
dation of JunD protein in these cells.
Results
Effects of TGF-1 on Proliferation of Prostate Cell Lines—We
have previously shown that TGF-1 exerts differential effects
on proliferation of different prostate cancer cell lines (15, 64).
To confirm these studies, we first determined the effects of
TGF-1 on proliferation of prostate cell lines representing spe-
cific stages of prostate cancer progression. Cells were plated
overnight (1  104 cells), serum-starved for 24 h, and then
treated with TGF-1 (1 and 10 ng/ml) for 18 h. Fig. 1 shows the
effects of TGF-1 on cell proliferation. As measured by
[3H]thymidine incorporation, TGF-1 caused a significant
dose-dependent inhibition of cell proliferation in RWPE1 and
DU145 cells but not in PC3 and LNCaP cells. Treatment with
TGF-1 resulted in 30% (1 ng/ml) (p  0.05) and 41% (10
ng/ml) (p  0.05) inhibition in RWPE1 cells and 24% (1 ng/ml)
and 38% (10 ng/ml) (p  0.05) inhibition of [3H]thymidine
incorporation in DU145 cells. LNCaP cells, which do not
express TGF- receptor II, served as negative control (Fig. 1).
Next, we treated DU145 and PC3 cells with TGF-1 (5 ng/ml)
to determine the stage of the cell cycle where TGF-1 exerted
its inhibitory effects. TGF-1 treatment led to an elevated num-
ber of cells in the G1 phase with a concomitant decrease in the
number of cells in S phase in DU145 cells (Table 1). Similar
treatment in PC3 cells did not cause any changes in cell num-
bers in different stages of the cell cycle.
Expression of Jun Family Members and Their Regulation by
TGF-1 in Prostate Cancer Cells—To establish a prostate can-
cer model system in which to observe any correlation of Jun
expression with prostate cancer progression, we first analyzed
expression of Jun family members in four prostate cell lines
using semiquantitative RT-PCR. Using gene-specific primers to
amplify mRNA encoding each member of this protein family,
all members of the Jun family were detectable in all four pros-
tate cell lines (Fig. 2A). To examine the presence of Jun proteins
in these prostate cell lines, the total cell lysate proteins were
analyzed using Western blotting analysis (Fig. 2B). All Jun pro-
teins were differentially expressed in all prostate cell lines.
Lower levels of c-Jun and JunD proteins were detected in
RWPE1 and LNCaP cells compared with DU145 and PC3 cells.
JunB levels, on the other hand, were higher in RWPE1 and PC3
cells.
To investigate a possible role of Jun family members in
TGF- effects on cell proliferation, we determined the effects of
TGF-1 on expression of Jun family members in DU145 and
PC3 cells. DU145 and PC3 cells (1  104) were plated overnight
and treated with TGF-1 (5 ng/ml) for different times. As
shown in Fig. 3A, TGF-1 had only a minor effect, if any, on the
mRNA levels of all Jun family members. However, at the protein
level, TGF-1 exerted significant effects on the levels of JunD,
c-Jun, and JunB in DU145 and/or PC3 cells in a time-dependent
manner (Fig. 3, B and C). JunB was significantly up-regulated in
both DU145 and PC3 cells after treatment with TGF-1 for 2 h
(DU145, 4.9  0.56-fold; PC3, 2.8  0.40-fold) (p  0.05) and
8 h (DU145, 4.0  0.96-fold; PC3, 2.5  0.39-fold) (p  0.05)
(Fig. 3C). Interestingly, TGF-1 significantly up-regulated
c-Jun in PC3 cells starting at 2 h (2.4  0.24-fold; p  0.05),
which stayed elevated for 24 h (1.8  0.46-fold, p  0.05) but
did not have any effect on c-Jun protein levels in DU145 cells.
FIGURE 1. Effects of TGF-1 on cell proliferation in different prostate cell
lines. RWPE1, LNCaP, DU145, and PC-3 cells were treated with different doses
of TGF-1 (5 ng/ml) for 18 h, and [3H]thymidine incorporation into DNA was
determined during a 4-h period. Each bar represents mean  S.D. (error bars)
from a representative experiment. *, significantly different from appropriate
controls (p  0.05).
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TGF-1 caused a significant down-regulation of JunD protein
in DU145 cells starting at 8 h (0.6  0.18-fold, p  0.05) but not
in PC3 cells. TGF- induced an increase in the levels of c-Jun
and JunB and caused a significant decrease in the levels of JunD
in RWPE-1 cells similar to those seen in DU145 cells, but not in
PC3 cells (data not shown). These results suggested that down-
regulation of JunD protein levels and/or up-regulation of c-Jun
and JunB protein levels in DU145 cells may play a role in
TGF-1 effects on inhibition of cell proliferation.
Role of Jun Proteins in Proliferation of Prostate Cancer Cells—
To determine the possible role of individual Jun proteins in
proliferation of prostate cancer cells and whether they play a
role in the effects of TGF- on cell proliferation, we used spe-
cific siRNAs to transiently knock down individual Jun proteins
in DU145 and PC3 cells (Fig. 4A). Control siRNAs were also
transfected to serve as negative control. Expression of Jun pro-
teins was determined by Western blotting analysis, which con-
firmed a marked down-regulation of the corresponding Jun
proteins in comparison with the cells transfected with the con-
trol siRNA (Fig. 4A). We analyzed proliferation of DU145 and
PC3 cells after knockdown of individual Jun proteins (Fig. 4A).
Transfection of JunD siRNA into DU145 or PC3 cells caused a
significant reduction in proliferation of both DU145 (82% inhi-
bition, p  0.05) and PC3 (71% inhibition, p  0.05) cells. On
the other hand, knockdown of either c-Jun or JunB had no sig-
nificant effect on cell proliferation in both cell lines. These
results suggested that JunD is required for proliferation of both
DU145 and PC3 cells.
To determine whether TGF-1 can further inhibit cell pro-
liferation after siRNA-mediated repression of JunD, DU145
and PC3 cells were treated with TGF-1 (5 ng/ml) for 48 h after
JunD siRNA transfection (Fig. 4B). As expected, after transfec-
tion with control siRNA, we observed a significant decrease
(p  0.05) in proliferation of DU145 cells and no effect in PC3
cells after treatment with TGF-1. In both cell lines, transfec-
tion with JunD siRNA resulted in significant inhibition of pro-
liferation, and TGF-1 treatment did not cause further
decrease in cell proliferation. These results suggest that
TGF-1 effects on proliferation of DU145 cells may be due to
its effects on down-regulation of JunD protein in these cells.
Knockdown of JunD and TGF- Treatment Exert Similar
Effects on Cell Cycle Arrest in the G1 Phase—To demonstrate
that TGF- effects on cell cycle arrest are mediated via down-
regulation of JunD, we compared the effects of JunD knock-
down with TGF-1 treatment on cell cycle machinery in
DU145 cells by FACS analysis. Knockdown of endogenous
JunD in DU145 cells resulted in an accumulation of cells in G1
fraction and a corresponding reduction in cells in S and G2/M
phases as compared with the siControl (Fig. 5A). These effects
are similar to those presented for TGF-1 treatment shown in
Table 1.
We also determined the levels of several proteins that play a
role in cell cycle regulation in DU145 cells after knockdown of
endogenous JunD or after treatment with TGF-1 for 24 h. We
have previously shown that TGF-1 induces a decrease in
c-Myc and Id1 proteins and an increase in p21 in DU145 cells
(15) as a part of its inhibitory effects on cell proliferation.
As shown in Fig. 5B, treatment with TGF-1 for 24 h or
knockdown of endogenous JunD exerted identical effects on
several cell cycle-associated proteins. There was a significant
decrease in the levels of c-Myc, Ki-67, and Id-1 proteins,
whereas there was a significant increase in the levels of p21.
Both treatments did not affect the levels of p27 in DU145 cells.
Interestingly, there was no significant decrease in the levels of
cyclin D1, and there was a slight increase in cells treated with
TGF-1.
JunD Knockdown Does Not Affect Cell Viability—To deter-
mine whether or not the knockdown of JunD results in
decreased cell viability, we used a TUNEL assay to assess apo-
ptosis in JunD siRNA transfected in DU145 cells (Fig. 5, C1 and
C2). We observed very few (1–2%) apoptotic positive cells in
both siControl and JunD siRNA-transfected cells. In addition,
we also determined the integrity of total nuclear DNA by DAPI
staining in both treatments (Fig. 5, C3 and C4). Again, there was
no significant differences in the nuclear DNA between the
treatments, indicating that knockdown of JunD has no effect on
viability of DU145 cells.
TGF-1 Does Not Affect JunD Phosphorylation or the SAPK/
JNK Pathway—To determine whether TGF-1 induces phos-
phorylation of JunD in DU145 cells prior to its degradation,
DU145 cells were treated with TGF-1 (5 ng/ml) at different
time points and analyzed for the levels of phospho-JunD and
total JunD by Western blotting analysis. As shown in Fig. 6A,
TGF-1 did not induce phosphorylation of JunD. In fact,
TGF-1 degraded basal phospho-JunD, mirroring total JunD
degradation. We also examined whether TGF-1 activates the
SAPK/JNK pathway. As shown in Fig. 6B, TGF-1 did not
induce phosphorylation of SAPK/JNKs.
TABLE 1
Cell cycle phase distributions of DU145 and PC3 cells after treatment
with TGF-1 (5 ng/ml)
Cell lines Treatment G1 S G2/M
DU145 Control 65.5  1.5 16.1  1.5 19.6  1.8
TGF-1 73.7  0.2a 11.9  1.9a 17.0  2.7
PC3 Control 45.4  1.3 18.3  2.1 36.3  0.8
TGF-1 46.3  2.0 20.6  5.4 33.1  3.4
a p  0.05, significantly different from appropriate controls.
FIGURE 2. Basal expression of Jun family members in prostate cell lines.
Cells were cultured under normal conditions for 24 h and lysed, and total RNA
and total proteins were prepared. A, total RNAs were analyzed for expression
of mRNA for individual Jun family members by RT-PCR. B, Jun family member
protein levels were determined by specific Western blotting analysis. L-19
and -actin were used as controls in RT-PCR and Western blotting analysis,
respectively.
JunD in TGF- Signaling in Prostate Cancer Cells
17966 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291 • NUMBER 34 • AUGUST 19, 2016
Generation of Stable DU145 Cell Lines Overexpressing Jun
Proteins and Effects of TGF-1 on Their Cell Proliferation—To
confirm the role of JunD in proliferation of prostate cancer
cells, pcDNA3.1 constructs carrying c-Jun, JunB, or JunD were
stably transfected into DU145 cells, and stable transfectants of
DU145 overexpressing c-Jun, JunB, or JunD cells were gener-
ated. Empty vector (pcDNA3.1) was also transfected into
DU145 cells to serve as a vector control. Multiple cell lines were
selected for each transfection, and their Jun protein levels were
analyzed by Western blotting analyses (Fig. 7A). Three lines
overexpressing each Jun protein were selected for cell prolifer-
ation assays (Fig. 7B). Cells were plated at an initial density of
1  105 and counted manually after 4 days. As shown in Fig. 7B,
DU145 cell lines overexpressing either c-Jun or JunB protein
exhibited similar or decreased proliferation compared with the
controls. In contrast, all cell lines overexpressing JunD exhib-
ited a significant increase in cell proliferation rate (2.7  0.07-
fold (D1), 3.4  0.34-fold (D5), 4.1  0.07-fold (D6); p  0.05).
To determine the effects of TGF-1 on the proliferation of
DU145-overexpressing Jun proteins, cells were plated over-
night at an initial density of 1  105 cells/well and were treated
the next day with TGF-1 (5 ng/ml). After 4 days, cells were
counted, and the data were analyzed. As shown in Fig. 7C,
TGF-1 significantly inhibited proliferation of DU145 cells
transfected with the empty vector (45% inhibition, p  0.05). It
also caused an inhibition of proliferation of DU145 cells over-
expressing JunB and c-Jun proteins, which was not statistically
significant. Surprisingly, TGF-1 also caused a significant inhi-
bition of proliferation in DU145 cells overexpressing JunD pro-
tein compared with the untreated cells (40% inhibition, p 
0.05).
JunD Promotes Colony Formation in DU145 Cells—To deter-
mine differential effects of Jun proteins on colony formation,
DU145 cells overexpressing Jun proteins and carrying empty
vector were cultured in soft agar and allowed to form colonies.
Each of the DU145 sublines was able to form colonies; however,
DU145 cells that overexpressed JunD showed greater (2.7-fold)
ability to grow in soft agar (30.3  3.2 clones, p  0.001 clones)
in comparison with the vector-only DU145 cells (11.0  0.8
clones) or the JunB (15.2  1.6 clones)- and c-Jun (10.2  0.5
clones)-transfected DU145 cells (Fig. 8).
Down-regulation of JunD by TGF-1 Is Dose-dependent and
Is Mediated through TGF- Receptors and via Ubiquitination
and Proteasome Degradation—The effect of TGF-1 on down-
regulation of JunD in DU145 cells was already significant at 1
ng/ml TGF-1 as shown in (Fig. 9A). No significant additional
effect can be observed with higher TGF-1 dosages. Preincu-
bation with inhibitors of TGF-RI (SB31542) and RII
(LY2157299) blocked TGF-1 induced reduction in JunD levels
in DU145 cells, even potentiating JunD levels (SB31542, 1.3 
0.13-fold, p  0.05; LY2157299, 1.6  0.26-fold, p  0.05),
indicating that JunD degradation was mediated through the
classical TGF- and Smad3 signaling mediated by TGF-
receptors (Fig. 9B).
To determine whether down-regulation of JunD protein in
DU145 cells in response to TGF- treatment involves protea-
FIGURE 3. Effects of TGF-1 on expression of Jun family members in DU145 and PC3 cells. A, levels of mRNA of c-Jun, JunB, and JunD in DU145 and PC3 cell
after treatment with TGF-1 (5 ng/ml) as determined by RT-PCR. B, the protein levels of c-Jun, JunB, and JunD from whole cell lysates of DU145 and PC3 cells
after treatment with TGF-1 (5 ng/ml) at different time points as determined by Western blotting analysis. C, quantitative analysis of relative levels of c-Jun,
JunB, and JunD proteins in DU145 and PC3 cells after treatment with TGF-1. Normalization was performed relative to the signal obtained with -actin. Each
bar represents mean  S.E. (error bars) (n  3). *, significantly different from untreated controls (p  0.05).
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somal degradation, we tested the effect of proteasome inhibitor,
MG132, on the levels of JunD protein following TGF-1 treat-
ment (Fig. 10A). After a 2-h pretreatment with MG132 (25 M),
DU145 cells were treated with TGF-1 (5 ng/ml) for 8 h. JunD
levels in DU145 cells, as expected, declined after 8 h (0.70 
0.14-fold, p  0.05) of TGF-1 treatment. MG132 itself raised
the JunD basal level in DU145 cells (1.74  0.33-fold, p  0.05).
However, TGF-1 treatment failed to cause a reduction in the
levels of JunD in the presence of MG132, suggesting that
TGF-1 down-regulates JunD levels via proteasomal degrada-
tion. Experiments described earlier showed that TGF-1 inhib-
its proliferation in DU145 cells overexpressing JunD (Fig. 7C),
suggesting that TGF-1 treatment may result in proteasomal
degradation of JunD in these cells as well. To confirm this
notion, DU145 cells overexpressing JunD (D6) were plated
overnight (4  105), pretreated with MG132 for 2 h, and then
treated with TGF-1 for 8 h. TGF-1 was able to down-regu-
late JunD protein in D6 cells (0.41  0.16-fold, p  0.05), and
MG132 pretreatment inhibited these effects of TGF-1 (Fig.
10B).
To examine the effects of TGF- on ubiquitination of pro-
teins, total cell lysates from DU145 cells were treated with and
without TGF-1 in the presence and absence of MG132 and
analyzed by immunoblotting with anti-ubiquitin antibody (Fig.
10C). The majority of ubiquitinated protein was observed in
cells treated with MG132, indicating that all proteins conju-
gated with ubiquitin were prevented from being degraded by
the proteasome. To examine the ubiquitination of JunD, total
cell lysates from the same experiment were subjected to im-
munoprecipitation using JunD antibody, and the resulting
precipitates were analyzed by Western blotting analysis with
anti-ubiquitin antibody (Fig. 10D). The majority of polyubiqui-
tinated JunD was detected in DU145 samples treated with
TGF-1 in the presence of MG132 compared with those with-
out TGF-1 treatment. These results confirmed that down-
regulation of JunD by TGF- is achieved through ubiquitina-
tion followed by proteasomal degradation.
Discussion
In this study, we demonstrate for the first time that JunD
plays an essential role in the proliferation of prostate epithelial
cancer cells. We also show that inhibitory effects of TGF- on
the proliferation of prostate epithelial cells depend on protea-
somal degradation of JunD, and failure of JunD degradation
may induce resistance to inhibitory effects of TGF- in
advanced stages of prostate cancer.
The AP-1 family proteins have been studied for many years,
and their involvement in cell proliferation, differentiation, dif-
ferentiated functions, and apoptosis has been documented
extensively (40, 65– 67). It has also been suggested by several
studies that expression of AP-1 proteins is associated with a
more aggressive clinical outcome in prostate cancer (47, 68, 69).
Most of these studies have, however, focused on the expression
and/or function of activated AP-1 complex containing c-Jun
FIGURE 4. Role of individual Jun family members in proliferation of DU145 and PC3 cells. DU145 and PC3 cells were transfected with either control or
specific Jun protein siRNA to knock down expression of individual family members. A, cell proliferation in DU145 and PC3 cells after transfection with control
(siControl-A), or JunB, JunD, or c-Jun siRNA. Each bar represents mean  S.E. (error bars) (n  3). *, significantly different when compared with appropriate
controls (p  0.05). Levels of Jun proteins after transfection with control siRNA and specific Jun siRNAs were determined by Western blotting analysis (inset). B,
cell proliferation in DU145 and PC3 cells after transfection with control or JunD siRNA and treatment with TGF-1 (5 ng/ml) for 4 days.
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and c-Fos (70). Consequently, the specific functions of individ-
ual AP-1 family members and various homo- and heterodimers
in the regulation of specific cellular processes remain largely
unknown. Therefore, in the current study, we focused on elu-
cidating the comparative roles of Jun family of proteins in pros-
tate cancer cell proliferation. Our results showed that all Jun
family members are constitutively expressed in various prostate
cell lines at the mRNA level but exhibited differences in the
levels of Jun proteins in various cell lines, indicating differential
regulation of proteins in different cell lines. The specific knock-
down of individual Jun family members by specific siRNA
showed that JunD plays an essential role in proliferation of both
DU145 and PC3 cells, whereas c-Jun and JunB knockdown had
FIGURE 5. Mechanism of inhibition of proliferation in DU145 cells by JunD. A, DU145 cells were transfected with either control (siControl-A) or JunD siRNA.
After 72 h, cells were fixed with 70% ethanol and stained with propidium iodide (50 g/ml). The DNA contents of the cells were measured by flow cytometry,
and the percentage distribution of the cells in the G1, S, and G2/M phases was determined. B, DU145 cells were either transfected with JunD siRNA for 72 h with
appropriate controls or treated with TGF-1 (5 ng/ml) for 24 h. A decrease in JunD levels in the JunD knockdown is compared with the decrease in the levels
of JunD after treatment with TGF-1. Protein levels for p21, p27, cyclin D1, Ki-67, c-Myc, and Id-1 were determined in total cell lysates by Western blotting. C,
assessment of apoptosis in DU145 cells transfected with JunD siRNA (bottom) and siControl-A (top). DU145 cells were transfected with JunD siRNA and control
siRNA for 72 h and then subjected to the TUNEL assay and DAPI staining. The TUNEL apoptosis assay (C1 and C2) was carried out to assess apoptotic cells. The
brown stain indicates apoptotic cells, whereas methyl green was used as a nuclear counter stain. DAPI staining (C3 and C4) was carried out to reveal any
condensation and formation of dense bodies characteristic of apoptosis.
FIGURE 6. TGF-1 did not induce JunD or SAPK/JNK phosphorylation in
DU145 cells. A, DU145 cells were treated with TGF-1 (5 ng/ml) for 0 min, 10
min, 30 min, 1 h, 2 h, and 4 h before cell lysis. Protein levels of phosphorylated
(p-) and total (t-) JunD and -actin were determined using Western blotting
analysis. B, DU145 cells were treated the same way with TGF-1 and then
analyzed by Western blotting analysis for phosphorylated and total JNK and
-actin. Anisomycin (250 ng/ml) was included as a positive control for JNK
activation.
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minimal effects on proliferation in these cell lines. The essential
role of JunD in proliferation of prostate cancer cells suggests
that an AP-1 complex containing a Jun-Jun homodimer or Jun-
Fos heterodimer containing JunD is responsible for positive
regulation of proliferation of these cells. Because c-Jun and
JunB knockdown did not influence cell proliferation, it is logical
to assume that they do not form dimers with JunD to induce cell
proliferation. Therefore, a dimer containing JunD-JunD or Jun-
Fos may be responsible for these effects. Additional studies are
needed to identify the JunD dimer partner that is required for
induction of cell proliferation in prostate cancer cells. The
essential role of JunD was also confirmed by our experiments
where we generated DU145 cell lines overexpressing individual
Jun family members. Whereas JunD overexpression resulted in
a significant increase in the proliferation rate, overexpression of
c-Jun or JunB resulted in a reduced proliferation rate. These
studies were further supported by increased colony formation
in DU145 cells overexpressing JunD compared with DU145
cells overexpressing c-Jun or JunB. These results suggest that
individual Jun family members exert distinct and even opposite
effects on proliferation of prostate cancer cells. Our results are
very similar to recently reported findings indicating that the
inhibition of JunD results in induction of several molecules,
such as GADD genes and JNKs, ultimately leading to prostate
tumor cell death and inhibition of tumor development (71).
These results are also supported by recent studies demonstrat-
ing that hydrogen peroxide-mediated proliferation is due to
binding of Fra-1/JunD and phospho-c-Jun to the HARP pro-
moter sites (57). JunD was also reported to be involved in
migration and invasion of prostate cancer cells by inducing the
expression of metalloproteinase-1-mediated by the Wnt5a sig-
naling pathway (72). Interestingly, this action of JunD on pros-
tate cancer cell migration was reported to be opposite to the
effect of JunB and c-Jun (73). JunD plays important regulatory
roles in both androgen-dependent and androgen-independent
prostate cancer cells by functioning as a co-activator for the
androgen receptor to mediate androgen-induced oxidative
stress in LNCaP cells (51, 74) or by interacting with the NFB
pathway to induce IL-6, an important mediator of metastatic,
hormone-refractory prostate cancer (75). On the other hand,
Church et al. (50) reported that cell growth inhibition in LNCaP
cells after treatment with androgens resulted in a concomitant
increase in JunD expression. This suggests that AP-1 regulation
of cell proliferation depends on the cellular “context” and on
the combination of available contributing factors and active
pathways in each target tissue.
TGF- is a multiple-function protein that acts as a tumor
suppressor in normal epithelial cells and in early stage cancer
FIGURE 7. Effects of overexpression of individual Jun proteins on cell proliferation in DU145 cells. A, Western blotting analyses showing levels of c-Jun,
JunB, and JunD proteins in DU145 subline cells after transfection with control (WT) or individual Jun plasmids. B, -fold change in the cell proliferation rate of
selected DU145 lines overexpressing c-Jun (C2, C4, and C5), JunB (B6, B7, and B9), and JunD (D1, D5, and D6). DU145 cells containing the empty vector were
used as controls. C, representative stable DU145 cell lines expressing each Jun protein were treated with TGF-1 (5 ng/ml) for 4 days, and total cell numbers
were counted. Each bar represents mean  S.E. (error bars) (n  3). *, significantly different when compared with appropriate controls (p  0.05).
FIGURE 8. Stable overexpression of JunD in DU145 enhances the
anchorage-independent growth of prostate cancer cell colonies on soft
agar. DU145 overexpressing c-Jun, JunB, or JunD and DU145 cells containing
empty vector, pcDNA3.1, were plated in 0.4% soft agar in complete growth
medium for 21 days, and cell colonies were counted. Each bar represents
mean  S.E. (error bars) from three independent wells.
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FIGURE 9. Down-regulation of JunD by TGF-1 is dose-dependent and is mediated through TGF- receptors. A, effects of different doses of TGF-1 (0, 1,
5, and 10 ng/ml) on JunD levels in DU145 cells treated for 8 h. B, effects of TGF-1 (5 ng/ml) on JunD levels in DU145 cells in the presence and absence of
inhibitors of TGF-RI (SB431542; 5 M) and/or TGF-RII (LY2157299; 10 M). Quantitative differences in JunD levels after different treatments are presented in
the bar graphs. Each bar represents mean  S.E. (error bars) from three independent experiments. *, significantly different when compared with controls (p 
0.05).
FIGURE 10. TGF-1 induces ubiquitination and proteasomal degradation of JunD. Western blotting analyses of JunD and -actin in DU145 (A) and DU145
cells overexpressing JunD (B). Cells were pretreated with MG132 (25 M) for 2 h and then treated with TGF-1 (5 ng/ml) for 8 h. Quantitative analysis of JunD
in DU145 and DU145 cells overexpressing JunD after treatment with TGF-1 in the presence or absence of MG132 is shown in bar graphs. Each bar represents
mean  S.E. (error bars) (n  3). *, significantly different when compared with controls (p  0. 05). C, equal amounts of total cell protein from DU145 cells treated
with and without TGF-1 for 8 h in the presence or absence of MG132 (25 M, 2 h pretreatment) were subjected to SDS-PAGE. All ubiquitinated proteins were
detected by Western blotting with anti-ubiquitin antibody. D, total cell lysates from different treatments were immunoprecipitated (Co-IP) using anti-JunD
antibody, and the immunoprecipitates were resolved on an SDS-PAGE and immunoblotted with anti-ubiquitin antibody.
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cells; cells in later stages of cancer become resistant to its
growth-inhibitory effects (13, 76). In advanced stages of the
disease, TGF- acts as a tumor promotor by virtue of its effects
on epithelial to mesenchymal transition, cell migration and
invasion, angiogenesis, and metastasis (77, 78). Our previous
studies and present results show that TGF- inhibits prolifera-
tion in RWPE-1 and DU145 cells, whereas PC3 cells are resist-
ant to these growth-inhibitory effects (15). On the other hand,
TGF- induces cell migration and invasion in PC3 cells but
does not affect migration and invasion in DU145 cells (16, 29,
64). Because both DU145 and PC3 cells express functional
TGF- receptors and Smad signaling (15, 29) but exhibit differ-
ential responses to TGF- treatment, we have exploited these
cell lines to understand differences in the signaling mechanism
that may act either downstream or parallel to Smad signaling
and are responsible for their differential responses to TGF-.
Our results show that TGF- induces a reduction in JunD pro-
tein levels in DU145 cells but not in PC3 cells. Because JunD is
required for cell proliferation, these results suggest that reduc-
tion of JunD levels in DU145 cells in response to TGF- may
lead to reduction in cell proliferation in these cells. On the other
hand, the lack of TGF- effects on PC3 cell proliferation may be
due to their resistance to TGF--induced reduction of JunD
levels. We previously showed that TGF- caused a down-reg-
ulation of Id1, a transcriptional regulator, in DU145 cells but
not in PC3 cells (15). Because Id1 knockdown by siRNA in both
DU145 and PC3 cells resulted in decreased proliferation in both
cell lines, we concluded that inhibitory effects of TGF-
required down-regulation of Id1 in prostate cancer cells (15).
Our current study shows that knockdown of JunD affected the
expression of several cell cycle regulatory proteins and also
caused a reduction in the expression of Id1. These results indi-
cate that JunD may regulate the expression of Id1 which, in
turn, may be required for cell proliferation. Our previous stud-
ies and our present results identify at least one distinct signaling
cascade, downstream of Smad2/3 activation, which may be
required for inhibitory effects of TGF- on cell proliferation
and which may be altered in the cells that become resistant to
growth-inhibitory effects of this cytokine. Treatment with
TGF- had no effect on JunD mRNA levels in both DU145 and
PC3 cells but caused a significant decrease in JunD protein lev-
els in DU145 cells. Furthermore, the effects of TGF- did not
involve phosphorylation of JunD or the activation of the JNK/
SAPK pathway, suggesting that reduced intracellular protein
levels are primarily responsible for the inhibitory effects of
TGF- on cell proliferation. Interestingly, TGF- treatment
also resulted in down-regulation of JunD protein and inhibition
of cell proliferation in DU145 cell lines overexpressing JunD,
suggesting post-transcriptional regulation of JunD expression.
The reduction in JunD protein levels was inhibited in the pres-
ence of proteasomal inhibitor, which also resulted in an
increase in the levels of ubiquitinated JunD protein in TGF--
treated cells, suggesting that TGF--induced reduction in JunD
levels is due to ubiquitination followed by proteasomal degra-
dation of the protein. The ubiquitin-proteasome pathway for
targeted degradation of proteins plays critical roles in a variety
of biological processes, such as cell cycle progression, signal
transduction, transcriptional regulation, receptor down-regu-
lation, and endocytosis (79, 80). The ubiquitin-proteasome
pathway tightly regulates TGF- family signaling (81– 84). In
this pathway, E3 ubiquitin ligases play a crucial role in the rec-
ognition and degradation of target proteins by the 26S protea-
somes (85). Smad degradation regulates TGF- family signal-
ing (86, 87). Our laboratory has previously shown that TGF--
induced degradation of Ski protein, a co-repressor of Smad2/3,
mediated by the proteasomal pathway is required for TGF--
induced biological responses in prostate cancer cells (16). The
identity of specific E3 ligase(s) and other components involved
in the degradation of JunD protein in response to TGF- is
currently not known, and it is plausible to assume that altera-
tions in these components may result in lack of responsiveness
to growth-inhibitory effects of TGF- in advanced stages of
prostate cancers.
On the basis of the results of the present study, we conclude
that JunD plays a critical role in the proliferation of prostate
cancer cells and may provide a significant therapeutic target for
the treatment of prostate cancers. Our studies also show that
c-Jun and JunB play a minimal role in induction of cell prolif-
eration in prostate cancer. In addition, proteasomal degrada-
tion of JunD in response to TGF- treatment is a prerequisite
for growth-inhibitory effects of this cytokine, and alterations in
the proteasomal pathway leading to lack of TGF- effects on
degradation of JunD may be partially responsible for resistance
to growth-inhibitory effects of TGF- in advanced stages of
cancer. These phenomena may underlie many cases of prostate
cancer with an otherwise intact TGF- signaling mechanism
and may represent an event earlier than the loss of TGF-
receptors in prostate cancer progression.
Experimental Procedures
Chemicals and Reagents—Recombinant human TGF-1 was
purchased from PeproTech (Rocky Hill, NJ). Proteasome/cal-
pain inhibitor, MG132, was acquired from Calbiochem. Inhib-
itors of TGF-RI (SB431542) and RII (LY2157299) were pur-
chased from Tocris Biosciences (Ellisville, MO) and Xcess
Biosciences Inc. (San Diego, CA), respectively. Anisomycin was
purchased from Calbiochem.
Human Jun cDNAs (c-Jun, JunB, and JunD) subcloned into
the pcDNA3.1() Mycstop expression vector along with the
empty vector were gifts from Dr. Curt Pfarr (Texas Tech Uni-
versity, El Paso, TX). Antibodies and siRNAs for Jun proteins
and antibodies against p21, p27, cyclin D1, c-Myc, and Id1 were
purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX).
The antibodies against ubiquitin, phospho-Smad3, phospho-
JunD, phospho-SAPK/JNK, and total SAPK/JNK were pur-
chased from Cell Signaling Technology, Inc. (Danvers, MA).
The antibody against Ki-67 was purchased from Calbiochem.
Anti--actin (clone AC-15) antibody was purchased from Sig-
ma-Aldrich. Goat anti-rabbit IgG HRP was purchased from Life
Technologies, Inc. Anti-mouse IgG HRP was obtained from GE
Healthcare.
Cell Lines and Cell Culture Conditions—Human prostate cell
lines (RWPE1, LNCaP, DU145, and PC3) were obtained from
American Type Cell Culture Collection (Manassas, VA). All
cells were cultured in the recommended growth media at 37 °C
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with 5% CO2 and 100% humidity as described previously (29,
64).
Cell Proliferation Assays—Cell growth assays were per-
formed using three techniques: thymidine incorporation, flow
cytometry, and manual cell counting. Each assay was per-
formed at least three times. For thymidine incorporation, cells
were seeded in a 24-well plate at a density of 4  104 cells/well
and maintained with 5% fetal bovine serum (FBS) overnight.
Cells were serum-starved for 24 h and treated with different
doses of TGF-1 (0, 1, and 10 ng/ml) in the presence of 1% FBS
for 18 h. Cells were then pulse-labeled for 4 h with 1 Ci/ml
[3H]thymidine (GE Healthcare), and the radioactivity incorpo-
rated into DNA was determined by liquid scintillation counting
as described previously (64). Flow cytometry was used to deter-
mine the cell cycle distribution of cells. Cells were plated at an
initial density of 1  106 cells/well overnight and then serum-
starved for 24 h. After treatment with TGF-1 (5 ng/ml) for
16 h, cells were harvested, washed twice with cold phosphate-
buffered saline (PBS), and fixed with cold 70% ethanol for 1 h on
ice. Cells were spun down and were incubated with propidium
iodide (50 g/ml) (Molecular Probes, Inc., Eugene, OR) and
RNase A (Bio-Rad) at room temperature for 30 min before they
were analyzed by flow cytometry. Cell cycle phase distribution
was determined from 1  104 cells using a BD Accuri Cytome-
ter (Ann Arbor, MI), following the manufacturer’s instructions.
For manual cell counting, cells were seeded at a density of 1 
105 cells/well overnight in a 6-well plate and, if needed, treated
the next day with TGF-1 (5 ng/ml) with 1% FBS at specific
time points. Cells were then trypsinized and counted using a
hemocytometer.
RNA Isolation, cDNA Synthesis, and RT-PCR—Cells were
seeded at a density of 5  105/well into a 6-well plate overnight
in the presence of 5% FBS. For DU145, PC3, and LNCaP cells,
their culture media were changed to 1% FBS after 24 h, whereas
for RWPE1 cells, culture medium was changed to EpiLife
medium. The cells were then treated with TGF-1 (5 ng/ml) for
0, 1, and 8 h. Total RNA was isolated from the cells using TRIzol
(Life Technologies) as described previously (88). 2 g of total
RNA were reverse-transcribed, and the resulting cDNAs were
diluted 4-fold with RNase-free water. 4 l of the diluted cDNA
were added to separate RT-PCR mixtures following established
procedures. All gene-specific primers were designed with Bea-
con-Designer version 5.0 as described previously (29). The
following primers were used: c-Jun forward, 5-TGGAAACG-
ACCTTCTATGACGA-3; c-Jun reverse, 5-GTTGCT-
GGACTGGATTATCAGG-3; JunB forward, 5-TACCACG-
ACGACTCATACACA-3; JunB reverse, 5-CGCTTTGAGA-
CTCCGGTAGG-3; JunD forward, 5-CAAACCCTGCCTT-
TCCTTTAC-3; JunD reverse, 5-GGCGAACCAAGGAT-
TACAAA-3; L19 forward, 5-GAAATCGCCAATGCCAA-
CTC-3; L19 reverse 5-TCTTAGACCTGCGAGCCTCA-3.
The PCR products were visualized on 1% agarose gels stained
with ethidium bromide (Amresco, Solon, OH). The relative
intensities of specific PCR bands were determined by ImageJ
version 1.48 (National Institutes of Health).
Western Blotting Analysis—Cells from different experiments
were washed twice with ice-cold PBS and were lysed in cell lysis
buffer (Cell Signaling Technology) containing 20 mM Tris-HCl
(pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1%
Triton, 2.5 mM sodium pyrophosphate, 1 mM -glycerophos-
phate, 1 mM Na3VO4, 1 g/ml leupeptin, and 1 protease
inhibitor mixture (Calbiochem). Protein concentrations were
determined by the Lowry HS assay using the Bio-Rad DC pro-
tein assay kit according to the instructions provided by the
manufacturer. Cell lysates were mixed with Laemmli’s buffer
(62.5 mM Tris, pH 6.8, 2% SDS, 5% -mercaptoethanol, and 10%
glycerol), and individual samples (35 g of protein) were sub-
jected to SDS-PAGE in 10% gels and transferred to PVDF mem-
branes (Millipore, Billerica, MA). The membranes were
blocked for 1 h at room temperature in 1 PBS (136 mM NaCl,
2.6 mM KCl, 4.3 mM Na2HPO4, 1.5 mM KH2PO4) and 5% fat-free
skim milk. The blots were then incubated overnight at 4 °C with
appropriate dilutions of specific primary antibodies (1:2000
dilution for anti-JunD; 1:1000 dilution for anti-c-Jun, anti-JunB,
anti-p21, anti-p27, anti-cyclin D1, anti-ubiquitin, anti-phos-
pho-JunD, anti-phospho-SAPK/JNK, anti-total SAPK/JNK,
and anti-phospho-Smad3; 1:500 dilution for anti-c-Myc and
anti-Ki-67; 1:10,000 dilution for anti--actin). After washing,
blots were incubated with appropriate immunoglobulin cou-
pled to horseradish peroxidase (dilution 1:20,000) for 1 h. The
blots were developed in Millipore Luminata Forte (EMD Milli-
pore, Billerica, MA) for 5 min and exposed to an x-ray film and
visualized either by autoradiography or by the Syngene PXI 6
imaging system (Syngene, Frederick, MD). Western blots for
-actin were carried out in parallel as loading controls. The
relative intensities of specific protein bands were determined by
ImageJ version 1.48 (National Institutes of Health).
Immunoprecipitation—DU145 cells were pretreated with
MG132 (25 M) for 2 h and then treated with TGF-1 (5 ng/ml)
for 8 h. Cells were lysed in cell lysis buffer (Cell Signaling Tech-
nology). Total cell lysates containing 500 g of proteins were
used for immunoprecipitation using procedures described previ-
ously (16). The resulting supernatants were incubated with 2 g of
anti-JunD antibody overnight at 4 °C. Immunocomplexes were
collected by centrifugation after incubation with protein A/G-Sep-
harose beads (Santa Cruz Biotechnology) and were analyzed by
Western blotting analysis with anti-ubiquitin antibody.
Transfection with Specific Jun Protein and Control siRNAs—
Cells were seeded at a density of 1.5  105 cells in 6-well plates
in 2 ml of antibiotic-free normal growth medium supplemented
with 5% FBS and incubated overnight at 37 °C. siRNAs (60 nM)
for the Jun proteins (c-Jun, JunD, JunB) or control siRNA were
transfected in DU145 and PC3 cells using transfection reagent
(Santa Cruz Biotechnology) following the manufacturer’s rec-
ommendations. 48 –72 h after transfection, cells were treated
with TGF-1 and/or subjected to different functional analyses.
Generation of DU145 Sublines Overexpressing Jun Proteins—
DU145 cells (1.5  105) were grown in a serum-free medium in
a 6-well plate and then transfected with the empty vector,
pcDNA3.1 Mycstop, or with pcDNA3.1 JunB Mycstop,
pcDNA3.1 Mycstop JunD, and pcDNA3.1 c-Jun Mycstop using
FuGENE HD transfection reagent (Promega, Madison, WI)
following the manufacturer’s instructions. For each gene trans-
fection, after 48 h, cells were trypsinized and replated to dilu-
tions of 1:2, 1:5, 1:10, 1:20, 1:40, and 1:80 in a 6-well plate,
supplemented with 5% FBS and G418 (800 g/ml) (Calbi-
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ochem). Cells were continuously fed with fresh medium con-
taining G418 every 2–3 days. About 1 week post-transfection,
single G418-resistant colonies were picked using sterile cloning
discs (Scienceware, Wayne, NJ) and grown to propagate. Total
proteins from the transfected lines were extracted, and Western
blotting analysis was performed to determine overexpression of
the specific Jun proteins. The effects of these transfections on cel-
lular proliferation were determined by cell counting.
TUNEL Assay and DAPI Staining—DU145 cells were seeded
onto coverslips at a density of 1.0  105 cells in 6-well plates in
2 ml of antibiotic-free normal growth medium supplemented
with 5% FBS. Transfection of control and JunD siRNA was per-
formed as described above. Cells were fixed with 3.7% formal-
dehyde in PBS for 20 min at room temperature. Cells were
permeabilized with 0.1% Triton X-100 for 20 min at room tem-
perature and then washed three times with PBS. Fixed cells
were evaluated for apoptosis using two independent methods; a
TUNEL assay was used to detect DNA fragmentation, which is
a hallmark of apoptosis in mammalian cells, and DAPI staining
was used to visualize intact total nuclear DNA. For the TUNEL
assay, apoptotic cells were detected using the proTUNEL-IHC
DNA fragmentation assay kit (GeneTex, Irvine, CA) following
the manufacturer’s recommendation. For nuclear visualization,
fixed cells were stained with DAPI (3 g/ml; Roche Applied
Science) following standard fluorescence staining protocols.
Coverslips were mounted on glass slides using Vectashield
mounting medium (Vector Laboratories, Burlingame, CA), and
then images were captured using 10 magnification with an
Axiovision camera of a Carl Zeiss 200M inverted fluorescence
microscope (Carl Zeiss, Thornwood, NY).
Soft Agar Colony Formation—A soft agar colony formation
assay was performed on DU145 cells overexpressing Jun pro-
teins in 6-well plates. Each well contained 2 ml of 0.6% agar in
complete medium as the bottom layer, 1 ml of 0.4% agar in
complete medium and 3000 cells as the feeder layer, and 1 ml of
complete medium as the top layer. Cultures were maintained
under standard culture conditions. The number of colonies was
determined with an inverted phase microscope (Carl Zeiss
200M) at 100 magnification. A group of 2 cells was counted as
a colony. The data presented are means  S.E. of 12 wells (total
number of colonies from 4 random fields/well) from two indepen-
dent experiments at an optimum time of 21 days after cell plating.
The experiment was repeated twice, with each experiment using a
different Jun-overexpressing DU145 cell line.
Statistical Analysis—All experiments were performed at
least three times using different cell preparations. Data from
representative experiments are shown in the figures. The sig-
nificance of the differences among treatments was determined
using one-way analysis of variance and Duncan’s multiple pair-
wise comparison tests using the statistical package from Sigma-
Plot version 11.0 for Windows.
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